To consider those findings, some researchers investigated the antitumor effect of the drug combination in NSCLC patients with EGFR mutation and suggested that the EGFR inhibitor and chemotherapy combination further improved the objective response rate [13]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.